Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
39.56%
median of 755 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Jade Biosciences, Inc.
Market Cap
$821.00M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$833.97M
Gross Margin
35.97%
TTM Avg
27.94%
3Y Avg
30.11%
5Y Avg
34.47%
Market Cap
$837.51M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$840.86M
Gross Margin
58.31%
TTM Avg
55.25%
3Y Avg
65.77%
5Y Avg
65.77%
Market Cap
$846.80M
Gross Margin
92.94%
TTM Avg
91.25%
3Y Avg
45.63%
5Y Avg
30.42%
Market Cap
$797.32M
Gross Margin
10.37%
TTM Avg
19.20%
3Y Avg
18.44%
5Y Avg
17.81%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | $821.00M | 0.00% | 0.00% | 0.00% | N/A |
| Ardelyx, Inc. (ARDX)vs › | $808.58M | 93.96% | 87.19% | 88.05% | 90.06% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $833.97M | 35.97% | 27.94% | 30.11% | 34.47% |
| InMode Ltd. (INMD)vs › | $806.17M | 76.52% | 79.43% | 81.57% | 82.72% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $837.51M | 0.00% | 0.00% | 0.00% | 0.00% |
| Beta Bionics, Inc. (BBNX)vs › | $840.86M | 58.31% | 55.25% | 65.77% | 65.77% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $846.80M | 92.94% | 91.25% | 45.63% | 30.42% |
| AdaptHealth Corp. (AHCO)vs › | $797.32M | 10.37% | 19.20% | 18.44% | 17.81% |
| Alumis Inc. (ALMS)vs › | $843.04M | 88.23% | 42.73% | 21.36% | 21.36% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $793.58M | 94.30% | 95.84% | 95.72% | 72.44% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
